Evidence map›Paper›PMID 40603615›Full record

ArticleSurgical endoscopy2025

Recurrent weight gain after sleeve gastrectomy: conversion to Roux-en-Y gastric bypass versus novel GLP-1 s.

Katherine Wasden, Vasundhara Mathur, Thomas J Martin, Thomas H Shin, Abdelrahman A Nimeri, Ali Tavakkoli, Eric G Sheu

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Katherine WasdenLaboratory for Surgical and Metabolic Research, Division of General and GI Surgery, Brigham and Women's Hospital, 75 Francis Street, ASBII-3rd Floor, Boston, MA, 02115, USA.
Vasundhara MathurLaboratory for Surgical and Metabolic Research, Division of General and GI Surgery, Brigham and Women's Hospital, 75 Francis Street, ASBII-3rd Floor, Boston, MA, 02115, USA.
Thomas J MartinLaboratory for Surgical and Metabolic Research, Division of General and GI Surgery, Brigham and Women's Hospital, 75 Francis Street, ASBII-3rd Floor, Boston, MA, 02115, USA.
Thomas H ShinLaboratory for Surgical and Metabolic Research, Division of General and GI Surgery, Brigham and Women's Hospital, 75 Francis Street, ASBII-3rd Floor, Boston, MA, 02115, USA.
Abdelrahman A NimeriLaboratory for Surgical and Metabolic Research, Division of General and GI Surgery, Brigham and Women's Hospital, 75 Francis Street, ASBII-3rd Floor, Boston, MA, 02115, USA.
Ali TavakkoliLaboratory for Surgical and Metabolic Research, Division of General and GI Surgery, Brigham and Women's Hospital, 75 Francis Street, ASBII-3rd Floor, Boston, MA, 02115, USA.
Eric G SheuLaboratory for Surgical and Metabolic Research, Division of General and GI Surgery, Brigham and Women's Hospital, 75 Francis Street, ASBII-3rd Floor, Boston, MA, 02115, USA. esheu@bwh.harvard.edu.ORCID http://orcid.org/0000-0003-2707-1768

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis retrospective cohort study aims to compare outcomes of Roux-en-Y gastric bypass (RYGB) versus semaglutide for treatment of recurrent weight gain (RWG) and suboptimal weight loss (SWL) after sleeve gastrectomy (SG).

methodsPatients at a tertiary care hospital who underwent RYGB conversion after SG (n = 87) were matched 1:1 to SG patients treated with semaglutide (n = 87) by: age, gender, race, ethnicity, pre-SG to pre-intervention total weight loss (%TWL), BMI, diabetes status, and time between SG and intervention. Semaglutide 'responders' (defined as ≥ 5% TWL at three months, n = 26) and non-responders were similarly compared to the overall RYGB cohort. Weight, comorbidity, and complication outcomes were collected for two years post-intervention.

results%TWL two years post-intervention was greater in the RYGB compared to the semaglutide cohort (17.1% vs. 7.6%, mean difference = 9.5%, 95% CI [2.6, 16.4], p = 0.002), as was the proportion of patients who achieved > 10% TWL (82.6% v. 40.9%, p < 0.001). Diabetes medications (p = 0.018) and mean HbA

conclusionsRYGB led to greater and more consistent weight loss and diabetes control than semaglutide in SG patients with RWG, at the cost of an increased need for GI interventions. While only a minority of patients responded to semaglutide, these patients had similar two-year weight outcomes as RYGB.

Indexed as

GastrectomyGastric BypassGlucagon-Like PeptidesHypoglycemic AgentsObesity, MorbidWeight GainAdultFemaleGlucagon-Like Peptide 1HumansMaleMiddle AgedRecurrenceRetrospective StudiesSemaglutideTreatment OutcomeGlucagon-Like Peptide 1Glucagon-Like PeptidesHypoglycemic AgentsSemaglutideBariatric surgeryGLP-1 agonistRecurrent weight gainRYGBSemaglutideSleeve gastrectomy

Identifiers

PMID40603615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.